AGN 193109 (sodium salt)

AGN 193109 is a potent antagonist of retinoic acid receptors (RARs, Kd = 2, 2, and 3 nM for RARalpha, beta, and gamma, respectively). It is selective for RARs over retinoid X receptors (RXRs, Kd = >10,000 nM for human RXRalpha, beta, and gamma receptors). AGN 193109 reverses changes in cell morphology induced by the RAR agonist TTNPB (Cay-16144) in ECE16-1 human endometrial ectocervical epithelial cells. It also reverses the growth suppressive effects of all-trans-RA, 13-cis-RA, and 9-cis-RA (Cay-14587) when used at a 10-fold molar excess. AGN 193109 decreases expression of cytokeratin K5-8, 13, 14, 16, 17, and 19 genes, markers of retinoid action in ECE16-1 cells, when co-administered with TTNPB but not when used alone. In vivo, AGN 193109 induces cleft palate or frontonasal dysplasia and eye malformations in fetuses of pregnant mice following a single oral dose of 1 mg/kg.Formal Name: 4-[2-[5,6-dihydro-5,5-dimethyl-8-(4-methylphenyl)-2-naphthalenyl]ethynyl]-benzoic acid, monosodium salt. CAS Number: 2319838-82-7. Synonyms: CD3106. Molecular Formula: C28H23O2 . Na. Formula Weight: 414.5. Purity: >98%. Formulation: (Request formulation change), A solid. Solubility: DMSO: Slightly Soluble, Methanol: Slightly Soluble. SMILES: CC(C=C1)=CC=C1C2=CCC(C)(C)C3=C2C=C(C#CC4=CC=C(C([O-])=O)C=C4)C=C3.[Na+]. InChi Code: InChI=1S/C28H24O2.Na/c1-19-4-11-22(12-5-19)24-16-17-28(2,3)26-15-10-21(18-25(24)26)7-6-20-8-13-23(14-9-20)27(29)30,/h4-5,8-16,18H,17H2,1-3H3,(H,29,30),/q,+1/p-1. InChi Key: JPAQKCQBQPEIHW-UHFFFAOYSA-M.